Intended for healthcare professionals


Montelukast: Regulator reviewing asthma drug over concerns about mental health effects

BMJ 2024; 384 doi: (Published 05 March 2024) Cite this as: BMJ 2024;384:q563
  1. Elisabeth Mahase
  1. The BMJ

The UK Medicines and Healthcare Products Regulatory Agency (MHRA) is investigating the risks associated with montelukast, which is used to treat asthma and allergic rhinitis, after concerns over neuropsychiatric reactions to the drug. It said its review will cover new data on risks, lack of awareness of side effects among patients, carers, and clinicians, and whether further regulatory action is needed.

The review comes after families of children who …

View Full Text

Log in

Log in through your institution


* For online subscription